Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. develops BETR-001, a proprietary non-hallucinogenic derivative of LSD and neuroplastogen, for psychiatric and neurological disorders. News about BETRF commonly covers scientific updates on BETR-001’s mechanism of action and neuroplastogenic activity, intellectual property and regulatory-preparation disclosures, and disease areas such as traumatic brain injury, post-traumatic stress disorder, cluster headache, depression and anxiety.
Company updates also include strategic partnering and conference participation, development alternatives for its viral-infection therapeutic candidate, debt settlements and warrant exercises, board and advisory appointments, and public-company disclosure matters in Canada and the U.S. OTC market.
BetterLife Pharma Inc. announced promising in vitro results for its recombinant human interferon alpha-2b (rhIFN⍺2b) against the Delta variant of SARS-CoV-2, achieving up to 97% protection in human cells. Further studies are ongoing to assess its effectiveness against other variants, including Gamma and Lambda. The company is conducting a Phase 1-2 trial in Chile, evaluating its inhaled therapy in early COVID-19 patients. CEO Ahmad Doroudian expressed optimism about overcoming therapeutic challenges posed by emerging variants.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has announced the successful acquisition of neurological receptor binding data for its lead compound, 2-bromo-LSD (TD-0148A). Conducted by Eurofins Discovery, the data suggests binding to key receptors linked to neuro-psychiatric disorders, indicating potential therapeutic applications. The company aims to advance TD-0148A towards IND status for clinical trials targeting conditions like depression and PTSD. Additionally, BetterLife welcomed David Melles as the new Investor Relations Manager to strengthen its investor engagement efforts.
BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has applied for patent protection for new compositions of 2-bromo-LSD, targeting cluster headaches, neuropathic pain, and mental health disorders like depression and PTSD. The second-generation LSD derivative, TD-0148A, is non-hallucinogenic and not subject to controlled substance regulations, facilitating its self-administration. The company is in advanced GMP manufacturing and preclinical IND-enabling studies, with plans to file an IND and commence Phase 1 and 2 trials in 2022.
BetterLife Pharma has initiated the IN2COVID trial in collaboration with Pontificia Universidad Católica de Chile, enrolling the first patient. This Phase 1-2 trial will evaluate AP-003, an inhaled interferon alpha-2b product, in COVID-19 patients. The trial includes a randomized placebo-controlled Phase 1 and a Phase 2 segment for patients diagnosed within five days. Dr. Ahmad Doroudian, BetterLife's CEO, expressed enthusiasm for the collaboration, while experts emphasized the need for effective treatments given emerging variants and breakthrough infections.
BetterLife Pharma has been invited to present at the Emerging Growth Conference on September 15, 2021. The company’s CEO, Dr. Ahmad Doroudian, will discuss the status of their neurological treatment programs, specifically focusing on compounds TD-0148A and TD-010. BetterLife’s presentation is scheduled for 11:15 AM Eastern Time.
Participants can engage with Dr. Doroudian live or watch a recorded version afterward. BetterLife is dedicated to treating neurological conditions, with a focus on depression and anxiety-related disorders.
BetterLife Pharma Inc. has partnered with Dr. John McCorvy at the Medical College of Wisconsin to conduct preclinical receptor binding studies for TD-0148A, a non-hallucinogenic LSD derivative aimed at treating cluster headaches and major depressive disorder. CEO Ahmad Doroudian highlighted the need for innovative therapies for psychiatric disorders. This partnership will explore TD-0148A's interaction with G protein coupled receptors to assist in its clinical development. BetterLife continues to focus on developing treatments for neurological conditions, with a market potential of nearly $25 billion for depression drugs by 2030.
BetterLife Pharma Inc. (CSE: BETR/ OTCQB: BETRF) announced the initiation of in vitro studies of its recombinant human interferon alpha-2b (rhIFN⍺2b or AP-003) against the Delta variant of SARS-CoV-2. Previous studies showed AP-003's potent antiviral activity against various COVID-19 strains. Results are expected within two weeks. The company's CEO emphasized the ongoing threat of COVID-19 variants and the need for effective treatments like AP-003, which could reduce hospitalization rates and severity of the disease.
BetterLife Pharma Inc. announced that its subsidiary, Altum Pharmaceuticals, alongside Pontificia Universidad Católica de Chile, received approval to conduct the IN2COVID trial in Chile. This randomized placebo-controlled trial will commence in early August, testing BetterLife's inhaled interferon alpha-2b product, AP-003, in COVID-19 patients. The trial aims to evaluate the safety and efficacy of AP-003, administered bi-daily for 10 days. BetterLife also focuses on developing compounds for neurological disorders, emphasizing the importance of effective treatment options amidst ongoing COVID-19 challenges.
BetterLife Pharma has announced funding support from Mitacs for a joint research project with Carleton University to explore the anxiolytic potential of TD-010, a compound aimed at treating anxiety and benzodiazepine dependency. TD-010, derived from honokiol, aims to provide a non-addictive alternative for patients with chronic anxiety disorders resistant to current therapies. The project will involve testing TD-010 using established models at Carleton's neuroscience department, highlighting the urgent need for safer anxiolytic treatments amidst rising benzodiazepine prescriptions.
BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF) announced its participation in the Emerging Growth Conference on July 21, 2021. CEO Dr. Ahmad Doroudian will present the company’s plans at 11:00 AM Eastern Time. Attendees will have the chance to ask questions during the session. Registered investors can also access an archived webcast post-event on EmergingGrowth.com. BetterLife focuses on developing compounds for neurological disorders, including TD-0148A for major depressive disorder and TD-010 for anxiety.